Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

TVTX

Travere Therapeutics Inc

Dec 08 • 04:00PM ET

8.64

Dollar change -0.01
Percentage change -0.12	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-4.40	Insider Own	5.53%	Shs Outstand	75.15M	Perf Week	34.58%
Market Cap	649.30M	Forward P/E	-	EPS next Y	-3.02	Insider Trans	-0.28%	Shs Float	70.99M	Perf Month	36.49%
Income	-312.99M	PEG	-	EPS next Q	-1.19	Inst Own	107.27%	Short Float / Ratio	15.01% / 5.38	Perf Quarter	-37.75%
Sales	209.65M	P/S	3.10	EPS this Y	62.85%	Inst Trans	0.11%	Short Interest	10.66M	Perf Half Y	-48.17%
Book/sh	3.72	P/B	2.32	EPS next Y	-85.83%	ROA	-41.95%	Target Price	14.27	Perf Year	-57.25%
Cash/sh	8.44	P/C	1.02	EPS next 5Y	-	ROE	-171.92%	52W Range	5.25 - 23.18	Perf YTD	-58.92%
Dividend	-	P/FCF	-	EPS past 5Y	-23.18%	ROI	-46.00%	52W High	-62.73%	Beta	0.50
Dividend %	-	Quick Ratio	4.77	Sales past 5Y	6.76%	Gross Margin	74.07%	52W Low	64.57%	ATR	0.60
Employees	462	Current Ratio	4.92	Sales Q/Q	-30.66%	Oper. Margin	-156.27%	RSI (14)	71.69	Volatility	10.35% 7.91%
Optionable	Yes	Debt/Eq	1.45	EPS Q/Q	9.40%	Profit Margin	-149.29%	Rel Volume	0.76	Prev Close	8.65
Shortable	Yes	LT Debt/Eq	1.43	Earnings	Nov 07 AMC	Payout	-	Avg Volume	1.98M	Price	8.64
Recom	1.56	SMA20	38.26%	SMA50	25.60%	SMA200	-40.92%	Volume	1,497,541	Change	-0.12%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-05-23	Upgrade	Citigroup	Neutral → Buy	$7 → $10
Nov-20-23	Initiated	Citigroup	Neutral	$7
Sep-22-23	Downgrade	Wells Fargo	Overweight → Equal Weight	$24 → $8
Sep-21-23	Downgrade	William Blair	Outperform → Mkt Perform
Sep-06-23	Resumed	Evercore ISI	Outperform	$30
Jul-21-23	Initiated	JP Morgan	Overweight	$26
Jun-07-23	Resumed	Piper Sandler	Neutral	$22
May-22-23	Initiated	TD Cowen	Outperform	$30
May-05-23	Upgrade	Bryan Garnier	Sell → Neutral
Mar-01-23	Initiated	Guggenheim	Buy	$37
Feb-21-23	Upgrade	Wedbush	Neutral → Outperform	$30
Dec-14-22	Initiated	Stifel	Hold	$22
Dec-05-22	Initiated	Wells Fargo	Overweight	$28
Sep-21-22	Initiated	Bryan Garnier	Sell	$17
Jul-14-22	Resumed	Canaccord Genuity	Buy	$49 → $42
Mar-31-22	Initiated	Piper Sandler	Overweight	$42
Feb-28-22	Initiated	H.C. Wainwright	Buy	$45
May-26-21	Downgrade	Wedbush	Outperform → Neutral	$19

Show Previous Ratings

Dec-04-23 04:05PM	Travere Completes Successful pre-NDA Meeting for FILSPARI in IgAN; Provides Regulatory Updates for both IgAN and FSGS (GlobeNewswire)
Nov-21-23 04:30PM	Travere Therapeutics to Present at the 6th Annual Evercore ISI HealthCONx Conference (GlobeNewswire)
Nov-09-23 06:26PM	Travere Therapeutics, Inc. (NASDAQ:TVTX) Q3 2023 Earnings Call Transcript (Insider Monkey) -14.06%
Nov-07-23 04:01PM	Travere Therapeutics Reports Third Quarter 2023 Financial Results (GlobeNewswire) +8.13%
Nov-03-23 10:46AM	Travere Therapeutics Announces Late-Breaking Data from Phase 3 Studies of Sparsentan in IgAN and FSGS Published in The Lancet and The NEJM Respectively and Presented at the American Society of Nephrology (ASN) Kidney Week 2023 (GlobeNewswire) +5.93%
04:30PM	Loading…
Oct-24-23 04:30PM	Travere Therapeutics to Report Third Quarter 2023 Financial Results (GlobeNewswire)
Oct-13-23 04:30PM	Travere Therapeutics to Present Abstracts at the American Society of Nephrology (ASN) Kidney Week 2023 (GlobeNewswire)
Oct-11-23 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-26-23 04:30PM	Travere Therapeutics to Present Abstracts at the 17th International Symposium on IgA Nephropathy (IIGANN 2023) (GlobeNewswire) +5.96%
Sep-22-23 09:38AM	Wayfair upgraded, Deere downgraded: Wall Street's top analyst calls (The Fly)
Sep-21-23 07:30AM	Travere Therapeutics Announces Confirmatory Data from the Phase 3 PROTECT Study of FILSPARI® Demonstrating Long-Term Kidney Function Preservation in IgA Nephropathy; Narrowly Missing eGFR Total Slope Endpoint versus Active Control, Irbesartan (GlobeNewswire) -40.68%
Sep-11-23 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-05-23 08:30AM	Travere Therapeutics Completes Sale of Bile Acid Product Portfolio to Mirum Pharmaceuticals (GlobeNewswire)
08:30AM	Mirum Pharmaceuticals Completes Acquisition of Bile Acid Product Portfolio for Treatment of Rare Liver Diseases from Travere Therapeutics (Business Wire)
Aug-31-23 04:30PM	Travere Therapeutics to Present at the 2023 Wells Fargo Healthcare Conference (GlobeNewswire) +8.26%
04:30PM	Loading…
Aug-24-23 04:30PM	Travere Therapeutics to Present Abstracts at the Society for the Study of Inborn Errors of Metabolism Annual Symposium 2023 (GlobeNewswire)
Aug-14-23 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-08-23 06:03AM	News Flash: Analysts Just Made A Notable Upgrade To Their Travere Therapeutics, Inc. (NASDAQ:TVTX) Forecasts (Simply Wall St.)
Aug-03-23 04:01PM	Travere Therapeutics Reports Second Quarter 2023 Financial Results (GlobeNewswire)
Jul-26-23 12:28PM	J.P. Morgan Recommends These 2 Strong Buy Stocks Including One With 90% Upside Potential (TipRanks)
Jul-20-23 04:30PM	Travere Therapeutics to Report Second Quarter 2023 Financial Results (GlobeNewswire)
Jul-17-23 08:00AM	Travere Therapeutics Enters Agreement to Sell its Bile Acid Product Portfolio for the Treatment of Rare Liver Diseases to Mirum Pharmaceuticals (GlobeNewswire)
08:00AM	Mirum Pharmaceuticals Enters Agreement to Acquire Bile Acid Product Portfolio for the Treatment of Rare Liver Diseases from Travere Therapeutics (Business Wire)
Jul-11-23 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-14-23 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-08-23 04:30PM	Travere Therapeutics Announces Presentations of Abstracts at the 60th European Renal Association (ERA) Congress 2023 (GlobeNewswire) -7.39%
Jun-01-23 04:30PM	Travere Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
May-31-23 07:00AM	Travere Therapeutics Announces Positive Topline Results from Cohort 6 in the Phase 1/2 COMPOSE Study of Pegtibatinase in Classical Homocystinuria (GlobeNewswire) +9.02%
May-11-23 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-04-23 04:01PM	Travere Therapeutics Reports First Quarter 2023 Financial Results (GlobeNewswire)
04:05PM	Loading…
May-01-23 04:05PM	Travere Therapeutics Announces Topline Results from Two-Year Primary Efficacy Endpoint in Pivotal Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis (GlobeNewswire)
Apr-26-23 04:30PM	Travere Therapeutics to Report First Quarter 2023 Financial Results (GlobeNewswire)
Apr-13-23 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-01-23 04:30AM	Travere Therapeutics Announces Interim Analysis from the Phase 3 PROTECT Study of FILSPARI (Sparsentan) in IgA Nephropathy Published in The Lancet and Presented at World Congress of Nephrology 2023 (GlobeNewswire)
Mar-28-23 04:30PM	Travere Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Mar-23-23 04:30PM	Travere Therapeutics Announces Late-Breaker Presentations of the Interim Analysis from the Phase 3 PROTECT Study of FILSPARI (Sparsentan) in IgA Nephropathy at the ISN World Congress of Nephrology and NKF Spring Clinical Meetings 2023 (GlobeNewswire)
Mar-14-23 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
04:30PM	Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders 44th Annual Meeting and the American College of Medical Genetics and Genomics Annual Clinical Genetics Meeting 2023 (GlobeNewswire)
Mar-03-23 04:05PM	Travere Therapeutics Announces Completion of Public Offering of Common Stock and Pre-Funded Warrants and Exercise in Full of Underwriters Option to Purchase Additional Shares (GlobeNewswire)
Feb-28-23 10:36PM	Travere Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
Feb-27-23 04:01PM	Travere Therapeutics Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Feb-25-23 07:35AM	Travere Therapeutics Full Year 2022 Earnings: Revenues Beat Expectations, EPS In Line (Simply Wall St.)
Feb-23-23 04:01PM	Travere Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire)
Feb-17-23 06:30PM	Ligands Partner Travere Therapeutics Announces FDA Accelerated Approval of FILSPARI (sparsentan), the First and Only Non-immunosuppressive Therapy for the Reduction of Proteinuria in IgA Nephropathy (Business Wire) -12.22%
04:04PM	Travere Therapeutics Announces FDA Accelerated Approval of FILSPARITM (sparsentan), the First and Only Non-immunosuppressive Therapy for the Reduction of Proteinuria in IgA Nephropathy (GlobeNewswire)
04:04PM	Travere Therapeutics Announces FDA Accelerated Approval of FILSPARI (sparsentan), the First and Only Non-immunosuppressive Therapy for the Reduction of Proteinuria in IgA Nephropathy (GlobeNewswire)
Feb-16-23 04:30PM	Travere Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire)
Feb-13-23 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-08-23 04:30PM	Travere Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Jan-12-23 07:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-09-23 07:00AM	Travere Therapeutics Provides Corporate Update and 2023 Outlook (GlobeNewswire)
Jan-03-23 04:30PM	Travere Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-14-22 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-16-22 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-15-22 08:00AM	Travere Therapeutics, the IgA Nephropathy Foundation, and NephCure Kidney International Partner to Launch RKD & Me, a Campaign to Raise Awareness of Rare Kidney Disease (GlobeNewswire)
Nov-09-22 04:30PM	Travere Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Oct-27-22 04:01PM	Travere Therapeutics Reports Third Quarter 2022 Financial Results (GlobeNewswire)
Oct-26-22 04:30PM	Travere Therapeutics Announces Presentations and Posters at American Society of Nephrology Kidney Week 2022 (GlobeNewswire)
Oct-20-22 04:30PM	Travere Therapeutics to Report Third Quarter 2022 Financial Results (GlobeNewswire)
Oct-13-22 04:05PM	Travere Therapeutics Provides Regulatory Update on its Sparsentan Program for IgA Nephropathy (GlobeNewswire)
Oct-11-22 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-14-22 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-25-22 04:30PM	Travere Therapeutics to Present Abstracts at the Society for the Study of Inborn Errors of Metabolism Annual Symposium (GlobeNewswire)
Aug-22-22 07:00AM	Travere Therapeutics and CSL Vifor Announce EMA has Accepted for Review the Conditional Marketing Authorization Application for Sparsentan for the Treatment of IgA Nephropathy (GlobeNewswire)
Aug-11-22 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-04-22 07:00AM	Travere Therapeutics Reports Second Quarter 2022 Financial Results (GlobeNewswire) +7.46%
Aug-03-22 04:05PM	Travere Therapeutics Provides Regulatory Updates on its Development Programs (GlobeNewswire)
Jul-28-22 04:30PM	Travere Therapeutics to Report Second Quarter 2022 Financial Results (GlobeNewswire)
Jul-12-22 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-20-22 09:18AM	Health Check: How Prudently Does Travere Therapeutics (NASDAQ:TVTX) Use Debt? (Simply Wall St.)
Jun-14-22 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-02-22 04:30PM	Travere Therapeutics to Present at the 2022 Jefferies Healthcare Conference (GlobeNewswire)
May-17-22 04:30PM	Travere Therapeutics Announces Presentations of Abstracts at the 59th ERA Congress (GlobeNewswire) +9.09%
May-16-22 04:09PM	Travere Therapeutics Pops After Snagging Priority Review For A New Kidney Drug (Investor's Business Daily) +6.13%
07:00AM	Travere Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for Sparsentan for the Treatment of IgA Nephropathy (GlobeNewswire)
May-11-22 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-05-22 04:01PM	Travere Therapeutics Reports First Quarter 2022 Financial Results (GlobeNewswire) -5.09%
May-03-22 04:30PM	Travere Therapeutics to Present at the BofA Securities 2022 Healthcare Conference (GlobeNewswire)
Apr-28-22 04:30PM	Travere Therapeutics to Report First Quarter 2022 Financial Results (GlobeNewswire)
Apr-20-22 04:30PM	Travere Therapeutics Announces Plan for Chief Financial Officer Transition (GlobeNewswire)
Apr-12-22 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-11-22 08:08AM	Travere Therapeutics' (NASDAQ:TVTX) growing losses don't faze investors as the stock ascends 5.1% this past week (Simply Wall St.)
Apr-06-22 04:30PM	Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders 43rd Annual Meeting and the Genetic Metabolic Dieticians International Conference 2022 (GlobeNewswire)
Mar-21-22 07:00AM	Travere Therapeutics Submits New Drug Application for Sparsentan for the Treatment of IgA Nephropathy (GlobeNewswire)
Mar-14-22 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-08-22 09:00PM	Travere Prices Upsized $275 Million Convertible Senior Notes Offering (GlobeNewswire) -11.47%
07:00AM	Travere Announces Proposed Convertible Senior Notes Offering (GlobeNewswire)
Mar-03-22 04:30PM	Travere Therapeutics to Present at the Barclays Global Healthcare Conference (GlobeNewswire)
Feb-28-22 08:00AM	Travere Therapeutics Recognizes Rare Disease Day 2022 and Raises Awareness for People Living with Rare Disease (GlobeNewswire)
Feb-24-22 04:01PM	Travere Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results (GlobeNewswire)
Feb-14-22 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-10-22 04:30PM	Travere Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results (GlobeNewswire)
Feb-09-22 04:30PM	Travere Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference (GlobeNewswire)
Feb-02-22 01:38PM	CM Management, LLC Buys Cadence Bank, Cadence Bank, Agnico Eagle Mines, Sells Cadence Bank, ... (GuruFocus.com)
Jan-28-22 05:38PM	Americana Partners, LLC Buys Adobe Inc, Apple Inc, Meta Platforms Inc, Sells Amazon. ... (GuruFocus.com)
Jan-12-22 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-11-22 10:54AM	Health Check: How Prudently Does Travere Therapeutics (NASDAQ:TVTX) Use Debt? (Simply Wall St.)
Jan-10-22 07:00AM	Travere Therapeutics Provides Corporate Update and 2022 Outlook (GlobeNewswire)
Jan-04-22 04:30PM	Travere Therapeutics Appoints Jula Inrig, M.D., as Chief Medical Officer (GlobeNewswire)
Dec-15-21 07:00AM	Travere Therapeutics Announces Positive Topline Results from the Ongoing Phase 1/2 COMPOSE Study of Pegtibatinase in Classical Homocystinuria (GlobeNewswire) +10.63%

Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. The firm's products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 7, 2008 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Heerma Peter	Chief Commercial Officer	Oct 03	Sale	8.25	3,091	25,504	80,257	Oct 04 04:05 PM
Dube Eric M	Chief Executive Officer	Sep 05	Sale	14.71	4,455	65,533	242,595	Sep 05 08:10 PM
ROTE WILLIAM E.	Senior Vice President, R&D	Sep 05	Sale	14.71	1,815	26,699	61,173	Sep 05 08:13 PM
REED ELIZABETH E	SVP, GC & Corporate Secretary	Sep 05	Sale	14.71	1,815	26,699	58,096	Sep 05 08:12 PM
Cline Christopher R.	Chief Financial Officer	Sep 05	Sale	14.71	457	6,723	50,574	Sep 05 08:15 PM
Calvin Sandra	SVP, Chief Accounting Officer	May 11	Sale	16.12	122	1,967	42,247	May 12 04:06 PM
REED ELIZABETH E	SVP, GC & Corporate Secretary	May 10	Sale	16.59	825	13,687	56,611	May 12 04:11 PM
ROTE WILLIAM E.	Senior Vice President, R&D	May 10	Sale	16.59	825	13,687	59,211	May 12 04:09 PM
Cline Christopher R.	Chief Financial Officer	May 10	Sale	16.59	455	7,548	51,031	May 12 04:14 PM
Calvin Sandra	SVP, Chief Accounting Officer	May 10	Sale	16.59	436	7,233	42,369	May 12 04:06 PM
Cline Christopher R.	Chief Financial Officer	Apr 11	Sale	21.49	47	1,010	51,486	Apr 13 04:07 PM
Calvin Sandra	SVP, Chief Accounting Officer	Feb 02	Sale	22.42	360	8,071	42,805	Feb 02 06:53 PM
Dube Eric M	Chief Executive Officer	Feb 01	Sale	22.25	8,196	182,361	237,150	Feb 02 06:58 PM
REED ELIZABETH E	SVP, GC & Corporate Secretary	Feb 01	Sale	22.25	2,590	57,628	57,436	Feb 02 07:11 PM
ROTE WILLIAM E.	Senior Vice President, R&D	Feb 01	Sale	22.25	2,590	57,628	60,036	Feb 02 07:08 PM
Heerma Peter	Chief Commercial Officer	Feb 01	Sale	21.75	1,779	38,697	82,069	Feb 02 07:04 PM
Calvin Sandra	SVP, Chief Accounting Officer	Feb 01	Sale	21.75	1,671	36,348	43,165	Feb 02 06:53 PM
Cline Christopher R.	Chief Financial Officer	Feb 01	Sale	21.75	1,588	34,542	51,533	Feb 02 07:02 PM
Calvin Sandra	SVP, Chief Accounting Officer	Jan 25	Sale	21.63	192	4,153	34,836	Jan 26 04:05 PM
Dube Eric M	Chief Executive Officer	Jan 24	Sale	21.50	6,442	138,503	147,846	Jan 26 04:05 PM
REED ELIZABETH E	SVP, GC & Corporate Secretary	Jan 24	Sale	21.50	2,062	44,333	39,776	Jan 26 04:05 PM
ROTE WILLIAM E.	Senior Vice President, R&D	Jan 24	Sale	21.50	2,062	44,333	42,376	Jan 26 04:05 PM
Heerma Peter	Chief Commercial Officer	Jan 24	Sale	21.90	1,550	33,952	63,598	Jan 26 04:05 PM
Calvin Sandra	SVP, Chief Accounting Officer	Jan 24	Sale	21.90	905	19,823	35,028	Jan 26 04:05 PM
Cline Christopher R.	Chief Financial Officer	Jan 24	Sale	21.90	852	18,663	32,871	Jan 26 04:05 PM
Dube Eric M	Chief Executive Officer	Jan 05	Sale	20.75	5,625	116,719	154,288	Jan 06 04:05 PM
Inrig Jula	Chief Medical Officer	Jan 05	Sale	20.75	442	9,172	17,507	Jan 06 04:05 PM
Inrig Jula	Chief Medical Officer	Jan 04	Sale	20.75	2,051	42,558	17,949	Jan 06 04:05 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

TVTX

Travere Therapeutics Inc

Upgrade your FINVIZ experience